625. De Luca G, Cassetti E, Verdoia M, et al. Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: a meta-analyis of randomised trials. Thromb Haemost. 2009;102: 428 36. 626. Stone GW, Moliterno DJ, Bertrand M, et al. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial. Circulation. 2002;105:2347 54. 627. Danzi GB, Capuano C, Sesana M, et al. Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutane- ous coronary intervention. Am J Cardiol. 2006;97:489 93. 628. Steinhubl SR, Kottke-Marchant K, Moliterno DJ, et al. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. Circulation. 1999;100:1977 82. 629. Gilchrist IC, O Shea JC, Kosoglou T, et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percuta- neous coronary intervention. Circulation. 2001;104:406 11. 630. Gurm HS, Tamhane U, Meier P, et al. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contem- porary randomized controlled trials. Circ Cardiovasc Interv. 2009;2: 230 6. 631. De Luca G, Ucci G, Cassetti E, et al. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angio- plasty: a meta-analysis. J Am Coll Cardiol. 2009;53:1668 73. 632. McKay RG, Boden WE. Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syn- dromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials. Curr Opin Cardiol. 2001;16:364 9. 633. The RESTORE Investigators. 